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1. Introduction
It has long been believed by many neurosurgeons that maximizing tumor resection improved
patient outcome for patients with high-grade gliomas. Over the past decade the impact of
maximizing tumor resection has been clearly shown to be a favorable prognostic factor in the
treatment of many types of brain tumors in clinical studies [1-11]. This holds true not only for
GBM and other high-grade gliomas but also for lower grade lesions as well [11-13]. In addition,
complete tumor resection has also been long known to be potentially curative for many
“benign” intracranial lesions such as meningiomas and pituitary tumors with much higher
rates of progression free survival for these types of lesions when complete resection has been
performed [14].
Even for the most experienced surgeon visual inspection and surgical judgment are not enough
to determine when complete resection has been obtained [3,15,16]. Too little resection increases
the chances for earlier recurrence and disease progression and overly aggressive resection
leads to an increased risk of potential neurological and cognitive deficits. As a result of this
many technological advances have been developed to try to assist the surgeon with determin‐
ing when complete resection has been obtained. These developments included intraoperative
ultrasound, frame based and frameless navigation systems, intraoperative MRI, and intrao‐
perative fluorescence with 5-aminolevulinic acid (5-ALA).
In addition, the utilization of awake mapping procedures also allows surgeons to maximize
tumor resection by enabling them to monitor the patient’s neurological status (motor or
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speech) throughout a resection. This real-time feedback enables surgeons to maximize tumor
resection in lesions near eloquent cortex while minimizing the development of neurological
deficits [17].
Figure 1. T1 Weighted post contrast preoperative and intraoperative MRI scans illustrating complete resection of a left
parietal GBM
2. Literature review of positive prognostic effect for extent of resection
(EOR)
One of the original studies to clearly show a survival advantage for extent of resection was a
large retrospective endeavor by LaCroix and the MD Anderson Group [1]. They showed a
survival advantage for extent of resection greater than 90% and an even greater advantage
when resection was over 97%. A 2012 review by Sanai found five studies which used volu‐
metric imaging to compare pre and postoperative MRIs for the EOR of contrast enhancement
for patients undergoing surgical treatment of primary GBM. Three of these studies showed a
survival advantage of between 2-8 months for patients undergoing complete resections
compared to subtotal resections [18]. He also found that seventeen out of twenty eight
nonvolumetric studies also found a survival advantage for extent of resection on univariate
analysis [18]. Fourteen of these twenty eight studies also performed multivariate analysis to
attempt to control for patient age, KPS and other factors. All fourteen of these papers found
extent of resection to be a positive prognostic factor using this type of analysis [18].
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In 2011 Sanai et al. [2] published a retrospective review evaluating extent of resection from a
retrospective series of 500 consecutive newly diagnosed GBM patients treated at the University
of California San Francisco Brain Tumor Center. Not only did they find a survival advantage
based on extent of resection; but they also showed that a resection threshold greater than 78%
was associated with a significant survival advantage. Although this study was retrospective
in nature, the large patient volume adds significantly to its importance and illustrates that even
in cases where complete resection may not be deemed safe that a significant debulking of
greater than 78% likely conveys a survival advantage versus less aggressive resections [2].
Finally Marko et al. [19] recently published another retrospective review of 721 primary GBM
patients treated at MD Anderson. They used an Accelerated Failure Time computer modeling
system to evaluate the effects of various parameters on patient outcome. They once again
showed a significant survival advantage for patients based on extent of resection. Unlike
previous studies they felt that there was an advantage across all levels compared to biopsy
alone and therefore felt that surgery should not be withheld based on preoperative assump‐
tions of only obtaining a subtotal resection. In addition, they also showed the strength of such
systems in reliably modelling outcome based on numerous patient and treatment parameters
and suggest possible uses for this system in determining personalized outcome models as well
as more appropriately stratifying patients for future clinical studies [19].
3. Elderly patients with GBM
At many institutions older patients with GBMs are not treated as aggressively as their younger
counterparts. Part of this problem is associated with higher rates of medical comorbidities
which may make more aggressive surgical interventions riskier. However, another bias is the
belief that elderly patients will not tolerate more aggressive procedures and subsequent
adjuvant treatments. Osvald et al. [20] performed a retrospective review of a large prospec‐
tively collected database to evaluate the impact of patient age on treatment. They found that
72% of patients younger than 65 were treated with resection vs. 55% of the older patients
(p<0.001). Elderly patients had lower KPS and significantly more medical comorbidities.
However, of the patients undergoing resection there was no statistical difference in the percent
that had gross total resection when the two groups were compared. Elderly patients had a
significantly decreased overall survival (9.1 months vs. 14.9 months), but subgroup analysis
of patients undergoing resection showed no difference in overall survival based on age (13.0
months for elderly vs. 13.3 months in younger patients) [20].
Grossman et al. [21] evaluated the effect of age on a group of patients undergoing awake
craniotomy for high-grade gliomas. They found perioperative morbidity (3.3% vs 0.59%) as
well as length of stay (6.6 vs 4.9 days) higher in the elderly group (age >65 years). The EOR
was not significantly different between the two groups (77.25 vs 81.9%).
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4. Recurrent GBM
The value of extent of resection for patients with recurrent GBM is even more difficult to
determine. Part of the issue in evaluating these patients is secondary to the bias created in
evaluating patients who are candidates for surgery, as less than 30% of patients are typically
deemed candidates for additional surgery. Factors in determining surgical eligibility include
patient performance, tolerance to previous treatments, patient wishes, and tumor factors such
as timing, size and location of recurrence [2,22-26].
Subgroup analysis of the Lacroix [1] paper showed a survival advantage for patients with
recurrent GBM who had maximal tumor resection at time of recurrence. In addition Bloch et
al. [7] evaluated the importance of extent of resection at the time of repeat surgery on a group
of 107 patients who underwent multiple resections at USCF. They found that if patients had
gross total resection at time of initial surgery than the extent of resection at recurrence did not
affect outcome; however, in patients who had subtotal resections at time of initial surgery than
the extent of resection at time of recurrence did impact overall survival. In addition, they found
that in patients who had an initial subtotal resection had a complete resection at recurrence
than there was no difference between them and patients who had complete resection initially
and were candidates for additional surgery regardless of extent of resection [7].
Oppenlander et al. [22] published results of 170 patients who were treated with recurrent GBM
at Barrow Neurological Institute. They found a distinct survival advantage based on an extent
of resection of 80% or greater in these patients. The median interval between initial and
subsequent surgery was 8.6 months (range 1.1-93.1 months) [22]. While these data do once
again show level 3 data of a survival advantage for these patients it is important to approach
this subgroup of patients with great care. First of all, early recurrence (less than 4-6 months)
should be approached with great hesitancy. Many of these patients harbor “treatment effect”
or pseudo-progression which can be managed medically in most of these patients. Secondly
patients who have true progression in this very short time frame often have very aggressive
tumor subtypes and are likely to progress despite further surgical interventions. My personal
practice is to typically withhold additional cytoreductive surgery in patients who have disease
progression prior to 6 months unless surgery is planned as a salvage intervention for symptom
management in an otherwise healthy individual, for tissue diagnosis, or to obtain tissue for
enrollment in a clinical trial. Finally, the incidence of wound healing and neurological
complications is much higher in this patient population. The Barrow group [22] reported
preoperative motor and language deficits in 33 and 31% respectively. Additionally they found
new or worsened deficits in 19% and 13% postoperatively at one week which only decreased
to 15% and 9% at one month [22]. These lesions are not curable and thus patient quality of life
is of paramount importance. Every effort should be made to minimize neurological worsening
in this patient population and thus judicious evaluation should be performed when deter‐
mining who is a candidate for additional cytoreductive surgery.
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Figure 2. Post contrast axial and coronal T1-weighted images of recurrent GBM, A. Preoperative; B. First intraoperative
(showing residual tumor along the lateral wall); C. Second intraoperative MRI scans
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5. Low grade gliomas
Once again in Sanai’s 2012 review [18] he found three papers which evaluated EOR for low
grade gliomas using volumetric analysis and all three of these showed a significant increase
in 5 year survival. He also reviewed eight nonvolumetric studies and once again found an
advantage in five year survival in 7 of these 8 studies. Five year survival was shown to increase
from 50-70% in cases with subtotal resection to 80-95% in total resections.
Several recent studies have also shown that increasing the extent of resection in low grade
gliomas may also decrease the rate of malignant transformation in these tumors. Typically
only pilocytic gliomas and other infrequent subtypes such as Ganglioglioma can be cured with
complete surgical resection. For the remainder of these lesions recurrence and often progres‐
sion to a higher grade lesion is the norm. Smith et al. [11] in their review of 216 low grade
lesions found that increased EOR was associated with increased malignant progression free
survival (MPFS). However, Snyder et al [12] reviewed the impact of EOR on overall survival
and MPFS in 93 pure grade II oligodendrogliomas treated at their institution. They found that
an increased EOR was associated with an improved OS but did not influence the rate or timing
of progression in these patients as MPFS was not influenced by EOR [12].
Figure 3. Axial T1-weighted preoperative and intraoperative scans showing low-grade non-enhancing tumor with re‐
sidual tumor positioned next to atrium on intraoperative scan, that was subsequently resected.
6. Methods to increase extent of resection
Despite the growing body of evidence leaning towards significant survival advantage in both
low and high grade gliomas, complete resection is often only obtained between 17-47% of cases
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[1,27-33]. Numerous intraoperative adjuncts have been trialed to help increase the EOR in these
procedures. Intraoperative frameless navigation is a mainstay in most North American Brain
Tumor Centers. This technology which is based on a preoperatively obtained imaging set has
been shown to be ineffective in increasing the EOR in a prospective randomized trial [34].
Upon opening the dura and proceeding with CSF drainage and tumor resection considerable
brain shift can occur which makes the information obtained from preoperative datasets
inaccurate (figure 4)[35].
Figure 4. Axial T1 weighted intraoperative MRI scan illustrating the extreme degree of brain shift that can occur with
opening the dura, drainage of CSF and tumor resection.
Orringer et al. [27] evaluated patient and tumor characteristics that might effect EOR in GBM
patients. Interestingly they found that based on postoperative MRI scans complete resection
was obtained in only 17% of cases despite the surgeon’s belief that GTR had been obtained
based on intraoperative assessments. They also found that larger tumors, lesions touching the
ventricles and lesions in or near eloquent cortex were associated with lower extent of resection
[27]. Of the 17 cases where complete resection was felt to be possible based on blinded review
of two experienced surgeons this was only obtained in four patients (23%)[27]. This study
clearly shows that the surgeon’s impression alone is not enough to maximize tumor resections
for these patients.
6.1. Ultrasound
Ultrasound was introduced as a surgical tool in the 1960s. This technology which typically
utilized low frequencies was extremely limited secondary to poor image resolution and
cumbersome intraoperative probes. The sensitivity and specificity of findings was limited
especially for highlighting small tumor remnants or differentiating tumor from edematous
brain. In addition, it was even more difficult to differentiate tumor from surrounding normal
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brain in low grade gliomas [36,37]. However, newer developments in ultrasound technology;
with the use of higher frequency devices, has created a recent resurgence in this technology.
New smaller light-weight probes can be placed within a resection cavity and give a much better
spatial resolution of surrounding areas. The use of higher frequencies improves image
resolution however this has a tradeoff of lower tissue penetration [38]. Serra et al. [38]
performed a retrospective review of 22 patients with high grade lesions (mixed pathology)
who they felt to be good candidates for gross total resection based on preoperative imaging
findings. High frequency intraoperative ultrasound was used for all patients. They found that
21 of the 22 patients had gross total resection of the enhancing lesion on postoperative imaging;
however, as the study was retrospective they were unable to determine how many patients
underwent additional imaging based on ultrasound findings.
6.2. Fluorescence guided resections
5-aminolevulinic acid (5-ALA) is an orally administered pro-drug which is metabolized
intracellularly to protoporphyrin IX which gives off a red-violet fluorescent signal to blue light.
This agent preferentially accumulates in certain tumor types and thus can be used to help
differentiate tumor from normal surrounding brain tissue [39]. The oral agent is administered
3 hours prior to surgery and then the operative field can be intermittently interrogated for
evidence of fluorescence throughout the procedure by switching back and forth between white
and blue light on the operative microscope.
Several prospective studies have been performed evaluating the benefits of 5-ALA in patients
undergoing surgical resection of high-grade gliomas [39]. Stummer et al [40] performed a
phase IIIa prospective study evaluating the impact of this technology on patients with high-
grade gliomas. The study was terminated early because interim analysis showed a significant
benefit in the study arm. Gross total resection was seen in 65% of patients in the 5-ALA arm
vs. 36% in the control group [40]. The utility of this technology only seems beneficial in patients
with high-grade lesions as significant accumulation has not been shown to occur in low grade
gliomas [41,42].
6.3. Intraoperative MRI
Intraoperative MRI (iMRI) was first used in Boston in the mid 1990’s. Since then numerous
revisions and variations of the technology have been performed. While significant expansion
in the number of centers with this technology has occurred in the past decade, cost is still the
limiting factor. The current technology can be divided into two categories based on magnet
strength. Low field systems such as the original 0.5 Tesla GE Signa SP (GE Medical Systems,
Milwaukee, WI) the 0.12 Tesla Odin Polestar table mounted system (Odin Technologies,
Yokneam, Israel); versus high-field systems which consist of 1.5 or 3.0 Tesla magnets. The high-
field systems all require cessation of the surgical procedure for imaging. Two subgroups exist
in this category. One in which the magnet is moved from a storage facility into the operating
theater via an overhead crane system (IMRIS Inc., Winnipeg Canada) and the other in which
the patient is moved from the operating theater into an adjacent ferrous free imaging zone
(figure 5). This use of this technology allows for intraoperative imaging for evaluation and
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confirmation of the anticipated surgical results. In addition, it also allows for intraoperative
updating of the navigation system to offset the changes that result from tumor resection and
brain shift. Each system has its own advantages and tradeoffs in terms of cost, ease of use and
image resolution [43].
Figure 5. Various Intraoperative MRI concepts (clockwise from top left: GE Signa SP double doughnut, IMRIS mobile
ceiling mounted system (scanner moves to patient), GE hybrid OR concept (inset shows close up of scanner; patient
moves to scanner), Odin table mounted system.
I [44] previously reviewed the results for treatment of GBM using the older GE Signa SP system
at Norton Healthcare (Louisville, KY) and found that additional surgical resection was
performed in 71.4% of cases based on intraoperative imaging results. The average EOR in this
patient group was 93.7% and was limited secondary to tumor location and vascular anatomy
in cases where EOR was less than 95%. Numerous other authors have shown the value of such
systems in increasing EOR [15,16,45-50].
Senft [6] performed a randomized controlled study looking at the utility of iMRI for treatment
of gliomas. All patients were felt to be candidates for complete resection based on preoperative
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imaging findings. Patients were randomized to undergo surgery with conventional microsur‐
gical techniques vs iMRI using the Odin Polestar system. In the study group the use of iMRI
led to additional tumor resection in 33% of patients with 96% of patients in the iMRI group
obtaining complete resection vs 68% in the control arm. Six month progression free survival
was 67% in the iMRI group compared to 36% in the control arm (p<0.05).
Roder et al. [51] compared a group of 117 patients treated with iMRI (IMRIS Visius System)
vs. a control arm treated with microsurgical techniques plus 5-ALA in some patients. 5-ALA
was used in 70% of iMRI patients and 60% of patients in the control arm. Complete tumor
resection was seen in 74% of the iMRI group vs 34% for the conventional group. Subgroup
analysis of the control group showed that complete resection in the conventional group
increased to 45% and mean residual volume decreased for patients who had 5-ALA fluores‐
cence as part of their procedure.
These studies all show a significant advantage for the use of this technology not only for high-
grade gliomas as outlined above but also for low-grade gliomas and pituitary tumors
[16,43,52-54]. However, despite the use of this technology complete resection is sometimes still
not possible. This can be secondary to tumor location in or near eloquent cortex, tumor adjacent
to the ventricle or tumor extending into deep or midline structures or associated around major
vascular structures[27,35,55,56]. Image interpretation during intraoperative procedures can
also lead to its own challenges. Tissue can become distorted and damaged secondary to
surgical trauma. This can lead to a disruption of the blood-brain barrier and thus increased
contrast enhancement. In addition, blood products and air in the surgical cavity can also distort
the imaging findings [35,43,44]. Finally the administration of contrast agents for preoperative
navigational studies the morning of surgery can also affect intraoperative imaging results. As
a result of these issues we routinely review all intraoperative imaging scans alongside an
experienced neuroradiologist in the iMRI control room during all procedures. Intraoperative
scans are directly compared to preoperative studies and when necessary any areas of ques‐
tionable residual tumor are directly investigated after the new dataset is downloaded to the
navigation system. Careful review of the imaging findings are necessary as overly aggressive
resections can lead to increased risk of new neurological deficits.
7. Awake mapping techniques
Regardless of the surgical techniques used for tumor resection the goal for extensive tumor
removal must always be tempered with the potential risk of inducing new or worsened
neurological injuries, as the patients postoperative neurological status is strongly correlated
with overall outcome. For lesions located in or near motor or speech centers intraoperative
mapping via electro-cortical stimulation can effectively identify these eloquent areas.
Newer developments in preoperative imaging such as functional MRI (fMRI) and diffusion
tensor imaging based fiber tracking (DTI-FT) can help to grossly localize the location of
eloquent cortex and their corresponding deep white matter tracts; however the accuracy of
exact localization is more reliably determined with intraoperative cortical and subcortical
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mapping techniques [57-64]. A meta-analysis of over 8000 patients who underwent craniotomy
for resection of intracranial glioma showed that patients who underwent intraoperative
mapping had a greater than two fold reduction in permanent neurological deficits [65].
Motor mapping can be performed either with the patient awake or under general anesthesia
(without muscle paralysis) while speech mapping requires the use of an awake anesthesia
technique at least during the mapping portion. Remifentanil and propofol or dexmetomidate
infusions are often used for these procedures as they have very short half-lives [17,55]. The use
of longer acting narcotics should be minimized as patients can become agitated and unco‐
operative with the over use of sedatives or narcotics. In addition an extensive local field block
of all regional nerves with a combination of a short and long-acting local anesthetic also helps
significantly with patient comfort and cooperation [17]. Patient selection is of paramount
importance as patients with severe edema, or significant pulmonary or airway issues may not
tolerate such a procedure. Time should be taken with the patient preoperatively to address
and concerns and thus minimize anxiety as well as to prepare the patient for their involvement
for the procedure. Complete details regarding the anesthesia for this technique are available
elsewhere [17,55]. I prefer to conduct all of my mapping procedures with an awake technique
regardless of whether speech function is being interrogated as having the ability to converse
with the patient and readily assess their neurological function is as important as localizing the
area of eloquent cortex. I have my anesthesiologist or operating room nurse regularly assess
the patients motor function throughout tumor resection, if speech cortex is involved we
routinely employ the assistance of a trained speech and language therapist who also assists
the patient in carrying on a conversation during tumor resection after mapping and stimulation
have been completed.
Mapping is routinely performed using a bipolar stimulation probe with 5 mm spacing between
the electrodes. Stimulation is performed at increasing amplitudes until a positive result in
encountered or after discharges are seen on electrocorticography or a upper threshold limit is
reached. The use of surface EEG is of great importance as it can minimize the risk of generalized
seizure activity induced by the stimulation and can verify that the stimulation system in
functioning adequately. A constant current generator is used to provide square biphasic wave
pulses for 1-4 seconds at 60Hz frequency (figure 6) [17,55,66]. Unlike epilepsy surgery where
positive stimulation results are almost always obtained the growing trend among tumor
surgeons is to perform smaller more tailored craniotomies for these cases. In these instances
negative stimulation results (with appropriate artifact on surface recordings) can be interpret‐
ed as absence of eloquent tissue [18]. Most authors recommend keeping a border of at least
0.8-1.0 cm of tissue between resection site and any site showing positive stimulation results
[17,18,55,66].
Subcortical stimulation can be performed using the same equipment and settings. The surgeon
must frequently alternate between deep white matter tract stimulation and tumor resection.
Resection is continued until either positive stimulation results are obtained or complete tumor
resection has been achieved. Higher rates of postoperative neurological deficits have been
shown in cases where positive motor stimulation is obtained during subcortical mapping,
likely secondary to manipulation in close proximity of these pathways [55,67].
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In appropriately selected patients awake mapping procedures can be performed safely with
minimal patient anxiety or discomfort. The information obtained from mapping and intrao‐
perative neurological assessment allows the surgeon to make a well informed decision
regarding the safety of continued resection vs. the risk of inducing new neurological deficits
(figure 7).
Figure 7. Preoperative and intraoperative axial T1-weighted post contrast scans; subcortical stimulation was positive
along the lateral and posterior border of the resection cavity thus a portion of the tumor was not resected.
Figure 6. Picture of intraoperative mapping case; #1 corresponds to area of lower extremity stimulation, #2 hand stimu‐
lation, #3 face stimulation, lesion is seen just anterior to #2 on surface of the brain.
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8. Conclusion: Combining technologies to obtain maximal safest results
I and several other authors have had experience combining several of these advanced tech‐
nologies together for the treatment of high risk patients undergoing treatment of intracranial
gliomas [44,45,56,68]. Select patients with lesions near or in eloquent cortex can undergo awake
mapping procedures with frequent neurological assessment to ensure the absence of gener‐
ating new neurological deficits. Intraoperative imaging can be performed once maximal tumor
resection has been performed to verify that the anticipated results have been obtained (figure
8). If significant residual tumors remains than the surgeon can immediately determine whether
further resection is deemed safe and continue with additional tumor removal while constantly
assessing the patients function or evaluating subcortical stimulation results. In cases where
the patient may be sedated but not intubated than transport of the patient into the scanner
does carry additional risks as the anesthesiologist has even more limited access to the patient
and their airway during imaging; however, I am unaware of any serious complications as a
result of performing iMRI on a mildly sedated non-intubated patient.
Figure 8. Preoperative and intraoperative axial T1-weighted post contrast images showing complete resection of a pos‐
terior left temporal lesion that was removed using an awake mapping technique in the intraoperative MRI.
One of the main drawbacks of the current high-field iMRI systems is the time required for
patient transport and scanning. For a majority of our cases we conduct only a single intrao‐
perative scan, typically if any residual tumor exists than further resection is performed based
off of updated neuronavigation results. In a minority of cases, typically those with large
volumes of residual tumor on the first scan, than a second confirmatory scan is performed.
The use of 5-ALA plus iMRI in patients with high-grade gliomas can further decrease the need
for additional scans. By maximizing the EOR based on the intraoperative fluorescence findings,
there is a higher likelihood of satisfactory results on the first scan, thus eliminating the need
for subsequent imaging. Any small or deep areas of residual tumor not appreciated with 5-
ALA can be seen on the iMRI images and resected with updated neuronavigation [51].
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